23 Sep 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Ventana Medical Systems, a member of the Roche Group, and Boehringer Ingelheim (BI) have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim Oncology programmes.
As part of the agreement, Ventana will utilize its immunohistochemistry technology platform, experience and expertise in companion diagnostic development and premarket approval (PMA) submissions to support Boehringer Ingelheim's personalised medicine healthcare strategies for cancer drug development.
Companion diagnostic tests provide information that aids physicians in choosing targeted treatments for their patients based on the expected best response to therapy. By integrating the development of companion diagnostic kits and drug candidates, Boehringer Ingelheim strives to yield cancer treatments with optimised benefit risk profiles.
"We are pleased that Ventana's commitment to enable Personalized Healthcare for patients worldwide was recognized by Boehringer Ingelheim when they selected Ventana to be a companion diagnostics development partner for their oncology programmes," said Mr Mara G Aspinall, president, Ventana Medical Systems.
"We look forward to partnering with Ventana and accessing their significant capabilities and expertise in developing companion diagnostics that will complement our products to further advance the delivery of personalized healthcare solutions for patients," said Mr Klaus Dugi, corporate senior VP, Medicine, Boehringer Ingelheim.